Jayalakshmi Sridhar
Post-doctoral Research Associate

Organic Chemistry Laboratory (CHEM 2230L and CHEM 2240L)

2009-present, Research Associate, Xavier University of Louisiana, New Orleans, LA,       USA.
2005-2008, Visiting Researcher, Department of Bioengineering, University of        California, Riverside, CA, USA
2002-2005, Postdoctoral position, Department of Neurosciences and Lombardi      Comprehensive Cancer Center, Georgetown University, Washington DC, USA.
1999-2001, Research Associate, Indian Institute of Technology, Chennai, India.
1998- Ph.D., Indian Institute of Chemical Technology, Osmania University, India.

Drug Design using Molecular Modeling and Computational Chemistry
We use molecular modeling and computational methods for structure based drug design, quantitative structure activity relationships (QSAR) of biologically active compounds, homology modeling of proteins and molecular dynamic studies. We are presently involved in two major areas of research, namely, development of new protein kinase inhibitors for cancer therapy and computationally analyze different aspects of inhibition of cytochrome P450 1A1, 1A2, 2A6, 2B1 and 1B1.

1. Jiang, Q.; Payton-Stewart, F.; Elliott, S.; Driver, J.; Rhodes, L. V.; Zhang, Q.; Zheng, S.; Bhatnagar, D.; Boue, S. M.; Collins-Burow, B. M.; Sridhar, J.; Stevens, C.; McLachlan, J. A.; Wiese, T. E.; Burow, M. E.; Wang, G. Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem 2010, 53, 6153-63.
2. Sridhar, J.; Jin, P.; Liu, J.; Foroozesh, M.; Stevens, C. L. In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem Res Toxicol 2010, 23, 600-7.
3. Kozikowski, A. P.; Gaisina, I. N.; Petukhov, P. A.; Sridhar, J.; King, L. T.; Blond, S. Y.; Duka, T.; Rusnak, M.; Sidhu, A. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem 2006, 1, 256-66.
4. Sridhar, J.; Akula, N.; Pattabiraman, N. Selectivity and potency of cyclin-dependent kinase inhibitors. AAPS J 2006, 8, E204-21.
5. Sridhar, J.; Akula, N.; Sivanesan, D.; Narasimhan, M.; Rathinavelu, A.; Pattabiraman, N. Identification of novel angiogenesis inhibitors. Bioorg Med Chem Lett 2005, 15, 4125-9.
6. Akula, N.; Bhalla, J.; Sridhar, J.; Pattabiraman, N. Binding modes of 6,7 di-substituted 4-anilinoquinoline-3-carbonitriles to EGFR. Bioorg Med Chem Lett 2004, 14, 3397-400.
7. Sridhar, J.; Wei, Z. L.; Nowak, I.; Lewin, N. E.; Ayres, J. A.; Pearce, L. V.; Blumberg, P. M.; Kozikowski, A. P. New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. J Med Chem 2003, 46, 4196-204.